Versant Ventures and RA Capital, two investment firms, led a €66m ($80m) Series A funding round in T-knife, a a next-generation adoptive T-cell company. The round was joined by Andera Partners and Boehringer Ingelheim Venture Fund. "Having worked in stealth mode to create a powerful humanized mouse platform bearing the human TCR loci, it is especially gratifying to now receive the validation from esteemed healthcare dedicated funds like Versant Ventures and RA Capital. We are equally grateful for the continued support of our founding shareholders, Andera Partners and Boehringer Ingelheim Venture Fund, two top-tier healthcare investors who have been our true partners since inception. Going forward, our goal is to become a transatlantic company by establishing a U.S. presence and expanding our management team accordingly," Elisa Kieback, T-knife Chief Executive Officer and Scientific Co-Founder.